Methods, Compositions, Systems, and Computer Program Products

JP2023547514A5Active Publication Date: 2024-11-07CLOSED LOOP MEDICINE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023526910
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-04
Filing Date
2021-11-04
Publication Date
2024-11-07
Estimated Expiration
2041-11-04

AI Technical Summary

Technical Problem

Current insomnia treatments are not effective due to their one-size-fits-all approach, failing to account for the various influencing factors that contribute to insomnia, leading to inconsistent results and limited efficacy.

Method used

A personalized treatment approach using melatonin is provided, which involves receiving sleep data, determining a dosing time based on this data, and indicating the appropriate time for melatonin administration to address individual insomnia issues.

Benefits of technology

This method enhances treatment effectiveness by synchronizing melatonin administration with a patient's sleep patterns, improving sleep quality and efficiency by controlling sleep starvation and aligning with circadian rhythms.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

1. A computer-implemented method for assisting in the treatment of insomnia with melatonin, comprising: receiving sleep data about a patient; determining, based on the sleep data, a dosing time for the patient to take a dose of melatonin; and indicating the dosing time.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] This disclosure relates to treatment support. [Background technology]

[0002] Insomnia is dissatisfaction with the quantity or quality of sleep. At some point in the year, one-third of the population has some difficulty falling asleep, staying asleep, or waking up early. Insomnia is typically accompanied by daytime sleepiness, low energy, irritability, and depressed mood. The physiological state of that one-third of the population differs measurably from that of the other two-thirds, with statistically elevated levels of adrenaline and cortisol, creating a “hyperarousal” physiological state. In one-third of that one-third (and therefore one in ten), it becomes a learned behavioral pattern, and the problem persists, as treatment revolves around forgetting the behavior.

[0003] There are many factors and causes that can lead to insomnia: sleep-disordered breathing, poor sleep hygiene, restless legs syndrome, hormonal shifts, fear, stress, anxiety, emotional or mental tension, work problems, financial stress, life events such as the birth or death of a child, circadian rhythm disruptions such as shift work and jet lag, increased exposure to blue light from artificial light sources such as telephones or computers, gastrointestinal problems such as heartburn or constipation, and many others.

[0004] Depending on the type of insomnia, a variety of treatment options are currently available. Typically, for the most common psychophysiological insomnias, treatment options, with or without medication, focus on behavioral modifications. Behavioral modifications include improving a person's "sleep hygiene," such as limiting caffeine intake, limiting exposure to light at night, exercising at appropriate times, and waking up at regular times.

[0005] Melatonin is a natural hormone released by the pineal gland, which regulates the sleep-wake cycle. Previous studies have suggested that melatonin supplementation may help increase the total sleep time of individuals suffering from sleep deprivation or changes in sleep schedule, but the evidence to support this is not strong. This may be due, at least in part, to the many different influencing factors and causes of insomnia, meaning that currently available "universal" general treatments are not effective for the diverse range of individuals suffering from insomnia. [Overview of the project]

[0006] This invention addresses the problems described in current insomnia treatment by providing an individualized treatment approach that takes into account various influencing factors affecting individuals suffering from insomnia. This results in a more effective treatment than those currently available.

[0007] According to a first aspect of this disclosure, a computer-based method for supporting the treatment of insomnia using melatonin, Receiving sleep data about patients, Based on sleep data, the timing of melatonin administration for the patient is determined, A method is provided that includes indicating the time of medication administration.

[0008] According to a second aspect, a system is provided for assisting in the treatment of insomnia using melatonin, comprising a processor configured to perform the method described in any one of the prior claims.

[0009] According to a third aspect, a computer program product is provided that stores computer executable instructions for performing the method defined in the first aspect.

[0010] According to the fourth aspect, melatonin is useful for treating insomnia, and a melatonin medication plan is, Receiving sleep data about patients, Based on the sleep data, determining the dosing time for the patient to take melatonin, and indicating the dosing time, are determined by steps including.

[0011] According to a fifth aspect, a method for treating insomnia, comprising administering melatonin to a patient who needs it, wherein the melatonin dosing plan receiving sleep data regarding the patient, and based on the sleep data, determining the dosing time for the patient to take melatonin, and indicating the dosing time, are determined by steps including, a method is provided.

[0012] According to a sixth aspect, melatonin is used in a manufactured pharmaceutical for the treatment of insomnia, and the melatonin dosing plan receiving sleep data regarding the patient, and based on the sleep data, determining the dosing time for the patient to take melatonin, and indicating the dosing time, are determined by steps including.

[0013] According to a seventh aspect, the kit includes melatonin and instructions for use, and the instructions for use include indicating the use of the computer-implemented method according to any one of claims 1 to 35.

[0014] The present disclosure is capable of following various modifications and alternative forms, and details thereof are shown in the drawings as examples and described in detail. However, it should be understood that other embodiments beyond the specific embodiments described are equally possible. All modifications, equivalents, and alternative embodiments falling within the spirit and scope of the appended patent claims are equally covered. [[ID=三十二]]

[0015] The above considerations are not intended to represent any exemplary embodiments or any implementations within the scope of the current or future patent claim sets. The following figures and the modes for carrying out the invention also illustrate various exemplary embodiments. The various exemplary embodiments can be more fully understood in connection with the accompanying drawings and in consideration of the following modes for carrying out the invention.

Brief Description of the Drawings

[0016] Referring to the accompanying drawings, one or more embodiments will be described only as examples. [Figure 1] A computer-implemented method according to an embodiment of the present invention is shown. [Figure 2] A system for executing any of the computer-implemented methods disclosed herein is shown.

Modes for Carrying Out the Invention

[0017] A first aspect of the present disclosure provides a computer-implemented method for assisting in the treatment of insomnia using melatonin. The method includes receiving sleep data regarding a patient, determining a dosing time for the patient to take a single dose of melatonin based on the sleep data, and indicating the dosing time.

[0018] The term "treatment" includes the improvement of a disease or condition, or its condition(s) (singular or plural). Treatment also includes the improvement of side effects of another therapy such as pharmacological therapy. Treatment also includes a reduction in a patient's dependence on another drug or behavior. "Improvement" is an improvement in a patient's condition, or a perceived improvement, or a change in a patient's condition that makes it increasingly tolerable, or a side effect.

[0019] The computer-based implementation method may be performed on a system comprising one or more processing devices. An exemplary system may include a single device such as a computer, or a mobile device such as a patient mobile device. The exemplary system may also include multiple physically distributed devices connected via a network such as a cellular network or the internet. For example, the multiple distributed devices may include a patient device, a server, and optionally a clinician device.

[0020] The term “support” refers to supplementary assistance to existing treatments for insomnia using melatonin. For example, the method may inform clinicians how to optimize treatment for insomnia using melatonin by indicating recommended dosing times. In other embodiments, the method may specifically instruct clinicians to optimize treatment by indicating optimal dosing times to patients. In other embodiments, if a patient has an existing melatonin prescription, the method may support treatment by directly indicating melatonin dosing times to the patient.

[0021] Treatment for insomnia may relate to different types of insomnia. For example, insomnia may relate to delayed sleep phase insomnia (referred to herein as Group A), early morning awakening insomnia (referred to herein as Group B), and sleep maintenance disorder insomnia (referred to herein as Group C). A patient may suffer from more than one type of insomnia. In certain embodiments, if a patient has Group A insomnia in addition to B or C, the treatment approach for Group A takes precedence. Group A insomnia (delayed sleep phase) can be defined as a patient having a delayed sleep phase component, where there is a delay of one hour, or more significantly, two hours or more, between the target sleep onset time and the actual sleep onset time. The target sleep onset time may refer to the optimal sleep onset time after prolonged negotiation. Thus, Group A relates to patients whose sleep onset time is delayed by more than two hours from the target or optimal "reasonable" sleep onset time. Group A does not include patients who, in their desperate attempts to get long hours of sleep, go to bed much earlier than their optimal bedtime (e.g., 9 p.m.) (e.g., 11 p.m.).

[0022] The terms "patient" and "subject" are used interchangeably and refer to the subject receiving melatonin. Preferably, the subject is a human.

[0023] The method involves receiving sleep data about the patient. The sleep data may include any data about the patient's sleep. The sleep data may include one or more of the following: wake-up time data, sleep duration, time to fall asleep, sleep quality, number of wake episodes, duration of wake episodes, and daytime sleep data.

[0024] Sleep data may include actual sleep data, which includes recorded data of the patient's actual sleep parameters. Actual sleep data may include one or more of the following: actual wake-up time, actual sleep duration, actual sleep onset time, actual sleep quality, actual number of wake-up episodes, actual duration of wake-up episodes, and actual daytime sleep duration.

[0025] Sleep data may include target sleep data, which includes target data that the patient should adhere to in order to progress to one or more patient goals (further discussed below). Target sleep data may include target wake time (also called established wake time), target sleep duration, target sleep hunger, and target sleep onset time.

[0026] Sleep data may include patient goal data, which includes the patient's desired sleep data. Patient goal data may include one or more of the following: desired wake-up time, desired sleep duration, desired sleep onset time, desired sleep quality, desired number of wake episodes, desired duration of wake episodes, and desired daytime sleep duration. In other embodiments, patient goal data may be received as further patient data.

[0027] It should be understood that sleep data may include one or more other sleep-related parameters. For example, sleep data may include one or more parameters that can be derived from the parameters listed above, such as sleep efficiency, which is equal to the actual duration of sleep divided by the actual time spent in bed.

[0028] Receiving sleep data may include receiving sleep data through input from the patient or clinician. For example, a patient may input or record actual sleep data after waking up in the morning. A patient may input patient goal data at the start of treatment support, or update patient goal data as treatment support progresses. A clinician may input initial sleep data when starting treatment support. A system implementing a computerized method may provide a user input module such as a keyboard, a touchscreen device, or other device known in the art. For example, a patient may input actual patient data or patient goal data via the touchscreen of a mobile device.

[0029] Receiving sleep data may also include receiving sleep data from one or more sensors. One or more sensors may include sensors capable of monitoring, recording, and / or evaluating a patient's sleep experience. One or more sensors may include motion sensors, video cameras, microphones, electroencephalograms (EEGs), heart rate monitors, pulse oximeters, or any other sensors capable of collecting polysomnography data. One or more sensors may be worn by the patient to whom the sleep data pertains.

[0030] Receiving sleep data may include receiving sleep data from one or more sensors that form part of the system implementing the method, for example, an accelerometer on a smartwatch. Receiving sleep data may also include receiving sleep data from one or more sensors that may be outside the system, for example, a separate medical device. The method may include communicating with one or more sensors to receive sleep data. The method may include processing raw sensor data to generate sleep data.

[0031] The method may also include receiving sleep data by retrieving it from a local or networked memory source. For example, the method may include receiving medical record data from a networked memory source.

[0032] The method may also include storing sleep data in a local or networked memory source. The method may further include storing any data required by or generated during the execution of the method. For example, the method may store additional patient data, determined medication times, actual medication times, processing errors, or any other relevant data.

[0033] The method further includes determining the timing of medication administration for a patient to take one dose of melatonin, based on sleep data.

[0034] The timing of medication may be a specific time, for example, 9 p.m., or a time relative to a parameter in the sleep data, for example, 16 hours after the actual wake-up time. The timing of medication may be for a single daily dose, or it may include multiple timings for medication at different times throughout the day.

[0035] The steps for determining the timing of medication administration will be discussed further below.

[0036] The method further includes indicating the time of medication. In some embodiments, indicating the time of medication may include directly showing the time of medication to the patient. Determining the time of medication and showing the time of medication may include determining the time of medication and showing the time of medication on a daily basis. Determining the time of medication on a daily basis may include determining the time of medication based on actual sleep data from the previous night's sleep or from several preceding nights' sleep (for example, based on a moving average).

[0037] In some embodiments, the method includes informing the clinician of the medication times. This may be to inform the clinician of recommended medication times or to instruct the clinician to prescribe medication times (and optionally, bedtime / target sleep time, as further discussed below). This may be done ad-hoc or regularly, such as weekly, bi-weekly, or monthly. In such embodiments, determining the medication times may be based on actual sleep data averaged over the intervention period. Alternatively, or in addition, determining the medication times may include determining the medication times on a daily basis and informing the clinician of the average daily medication times.

[0038] Therefore, in the following discussion, all types of data, including sleep data, particularly actual sleep data and any further patient data, may include daily data such as daily actual sleep data corresponding to data for a specific day (e.g., specific actual wake times for a particular day), or average data such as average actual sleep data corresponding to multiple days (e.g., average actual wake times for multiple days). The method may include determining a moving average of daily data (such as a 3-day moving average or a 7-day moving average) for any of the data types measured, received, determined, or indicated by the method (such as sleep data, actual sleep data, medication times, or any further patient data). While the data is described as daily, it should be understood that the timing precision of a particular data type may include timing resolution of minutes, seconds, or higher precision.

[0039] Returning to the step of determining the timing of medication, determining the timing of medication may be based on one or more parameters of sleep data. In one embodiment, determining the timing of medication may be based on wake-up time data. Wake-up time data may include actual wake-up time and / or target wake-up time. The target wake-up time may be referred to as the fixed wake-up time. The method may determine the timing of medication based on the target wake-up time in a way that fixes this target wake-up time in an attempt to fixate the patient's sleep pattern over several days. In this way, the method can fix or fix the target wake-up time regardless of the patient's sleep on a particular day in an attempt to synchronize the patient's long-term sleep pattern with the actual wake-up time which tends toward the target wake-up time.

[0040] To further understand the concept of establishing a consistent wake-up time, let's look at two main drivers of falling asleep. 1. Sleep homeostat, also known as "sleep motivator," "sleep deprivation," or "sleep debt." This sleep deprivation can be approximated as the length of time a patient is awake. 2. Circadian rhythms. In particular, an increase in natural melatonin levels opens a window for sleep opportunities.

[0041] The onset of sleep or falling asleep is most likely to occur when 1 and 2 are synchronized.

[0042] The remaining portion of natural melatonin secretion at night is thought to promote nocturnal sleep, which in humans is normal (non-insomnia) sleep.

[0043] The first aspect of the method involves determining the timing of exogenous melatonin administration, i.e., melatonin-based treatment, such that the subsequent rise in melatonin levels (from a low baseline) coincides with a sufficient amount of sleep deprivation to initiate sleep. The required sleep deprivation level may be higher than "normal" to overcome the triggers of insomnia-related anxiety that may contribute to insomnia in the first place. In other words, the patient may require a higher degree of sleep deprivation and therefore need to go to bed later than when insomnia is absent or "cured."

[0044] Therefore, the method can assist in the treatment of insomnia by controlling sleep deprivation. The method can control sleep deprivation by fixing wake time. The method can fix wake time by receiving a target wake time and an actual wake time and determining the medication time based on the target wake time and the actual wake time. In one or more embodiments, the method may include determining the medication time as a fixed time following either the actual wake time or the target wake time, depending on which time occurs first.

[0045] The method may include determining the timing of medication based on the target time to fall asleep. In some embodiments, sleep data may include the target time to fall asleep (such as that received from patient and / or clinician input). In some embodiments, the method may include determining the target time to fall asleep based on the target time to wake up and / or the actual time to wake up. For example, the method may determine the target time to fall asleep to correspond to a fixed time following the actual time to wake up or the target time to wake up, depending on which time occurs first. The fixed time may correspond to sufficient sleep deprivation. The method may determine the timing of medication as a further fixed time prior to the target time to fall asleep.

[0046] To illustrate one embodiment, a method may support the treatment of insomnia with melatonin for group A insomnia. The method may include receiving a target wake-up time and an actual wake-up time. The method may include determining the medication time as 8 to 12 hours, preferably 10 hours, after the actual wake-up time or the target wake-up time. In some embodiments, determining the medication time includes determining the medication time as 8 to 12 hours, preferably 10 hours, after the later of the actual wake-up time or the target wake-up time. For a stable, established wake-up time (actual wake-up time to target wake-up time), 10 hours after the actual wake-up time corresponds to the medication time for taking melatonin, which is 12 hours before the lowest point of the patient's nocturnal body temperature, which is 2 hours before the actual wake-up time. Therefore, for a stable, established wake-up time, the medication time corresponds to 14 hours before the target wake-up time.

[0047] To illustrate further embodiments, the method may assist in the treatment of insomnia using melatonin for insomnia of group B or C type. The method may include receiving a target wake-up time and an actual wake-up time. The method may include determining a dosing time as 11 to 19 hours, preferably 15 hours, after the actual wake-up time or the target wake-up time. In some embodiments, determining the dosing time includes determining the dosing time as 11 to 19 hours, preferably 15 hours, after the later of the actual wake-up time or the target wake-up time. The dosing time 15 hours after the target wake-up time corresponds to subtracting from 24 hours the average sleep time per day (8 hours in this example) calculated for that patient and further subtracting 1 hour (the dosing offset time described further below) related to taking melatonin 1 hour prior to the sleep onset time.

[0048] Thus, more generally, the method may include determining a dosing time based on the actual wake-up time, the target wake-up time, the target sleep duration, and the dosing offset time. For example, determining the dosing time may include adding 24 hours to the actual wake-up time t AW , or the target wake-up t TW ime (the later of the two), subtracting the target sleep duration t TSD , and subtracting the dosing offset time t DO [[ID= twelfth]] to determine the dosing time t dose . t dose = the later of (t AW , t TW ) + 24 - t TSD - t DO

[0049] The target sleep duration may be based on the average sleep duration of the patient or the "normal" sleep duration of the patient (e.g., 8 hours). However, the normal or average sleep duration generally follows a normal distribution in the population, and the normal sleep duration may be personal to the patient. The method may determine the target sleep duration based on sleep data or further patient data. The target sleep duration may be based on or equal to the desired sleep duration.

[0050] The medication offset time defines the time between the medication administration time and the target sleep onset time or target bedtime. The medication offset time can be 0 to 3 hours, preferably 1 hour. By taking melatonin one hour before the target sleep onset time, the increase in the patient's melatonin level can be coordinated with the target sleep onset time.

[0051] The term "24 hours minus target sleep duration" can correspond to an equivalent target sleep hunger. For example, an 8-hour target sleep duration corresponds to a 16-hour target sleep hunger. Target sleep hunger can be considered the target time between the actual or target wake-up time and the target sleep-on / sleep-to-bed time. Target sleep hunger may include the optimal sleep hunger for achieving sleep onset. Therefore, determining the timing of medication involves the target wake-up time, actual wake-up time, and target sleep hunger. SH This may include determining the timing of medication administration based on the medication offset time. t dose =( t AW ,t TW ) The slower of the two + t TSH -t DO

[0052] In further embodiments, the method may include an intermediate step of determining a target sleep onset time based on a target wake-up time or actual wake-up time. Determining the target sleep onset time is related to the medication time t dose As for the actual wake-up time t AW or target wake-up time TW This may include determining the target time to fall asleep by adding 24 hours to the later of the two time periods and subtracting the target duration of sleep. t dose =( t AW ,t TW ) The slower of the two + 24-t TSD

[0053] Alternatively, determining the target time to fall asleep is related to the medication time. dose As for the actual wake-up time t AW or target wake-up time TWThis may include determining the target time to fall asleep by adding the target hunger level to the later of the two time periods. t dose =( t AW ,t TW ) The slower of the two + t TSH

[0054] Determining the target sleep onset time may involve determining the target sleep onset time as 12 to 20 hours, preferably 16 hours, after the actual wake-up time or the target wake-up time. The method may involve determining the medication time based on the target sleep onset time, for example, the target sleep onset time minus the medication offset time. By taking melatonin at the medication offset time before the target sleep onset, the increase in the patient's melatonin level can be coordinated with the target sleep onset time / target sleep hunger. In this way, the method can control the increase in melatonin level in synchronization with optimal sleep hunger.

[0055] In some embodiments, the method may include receiving sleep data, including an insomnia severity assessment, and applying a severity offset to the medication time based on the insomnia severity assessment. The method may additionally or alternatively include applying the severity offset to the target sleep onset time. For example, a patient with a moderate severity assessment may exhibit mild insomnia-related arousal factors corresponding to a 1-hour severity offset. A patient with a high severity assessment may exhibit severe insomnia-related arousal factors corresponding to a 2-hour severity offset.

[0056] In some embodiments, the method may include determining the timing of medication based on sleep data other than wake-up data. For example, as discussed above, the method may include determining the timing of medication based on the target time to fall asleep. In some embodiments, determining the timing of medication may be based on the target sleep hunger. Alternatively, or in addition, determining the timing of medication may include determining the actual sleep hunger based on sleep data. Determining the actual sleep hunger may be based on the actual time to fall asleep and the total sleep duration. The total sleep duration may include the nighttime sleep duration and the daytime sleep duration. Methods according to such embodiments can still achieve the same effect of establishing the actual wake-up time and medication timing as the patient settles into a regular medication routine.

[0057] The method may further include receiving additional patient data. This additional patient data may include one or more of the following: personal patient data, patient record data, patient physiological data, patient goal data, environmental data, patient medication data, and patient activity data.

[0058] Receiving further patient data may include receiving further patient data through one or more of the following: user input (e.g., data entered by the patient), sensor input (e.g., data from patient sensors such as a heart rate monitor, or data from system sensors such as a temperature sensor), or network input (e.g., patient record data or environmental / weather data may be communicated via a network connection).

[0059] Personal data may include basic patient information such as age, gender, weight, and BMI.

[0060] Patient record data may include medical records containing information such as medical history, comorbidities, and prescription data. Patient record data may also include personal patient data.

[0061] Patient physiological data may include data on one or more physiological measurements. Such measurements may be taken by the patient, the healthcare provider, or by a device such as an electronic device, a smartphone, or other handheld device. Exemplary physiological measurements include heart rate, blood pressure, oxygen saturation, and respiratory rate.

[0062] Patient goal data may include desired sleep data as described above in relation to sleep data. Patient goal data may further include desired medication goals, which may include discontinuing melatonin-based medication.

[0063] Environmental data may relate to the patient's environment, such as the patient's local environment. Environmental data may include one or more environmental measurements. Suitable environmental measurements may include temperature, humidity, and / or light intensity, such as daily exposure, electron light exposure, daily average temperature, daily maximum / minimum temperature, and daily rainfall.

[0064] Patient drug data may include medication information regarding the patient's melatonin prescription, including dosage, frequency, and duration. Drug data may include records of actual medication use. Actual medication use data may include the patient's timing of administration, dosage, missed doses, etc. Actual medication use data may be entered by the patient or received via communication with smart drug packaging. Drug data may include further prescription data about the patient for other medications.

[0065] Patient activity data may include any activities that may affect a patient's sleep ability. Illustrative patient activity data may include intake data, including exercise data, food intake data, caffeine intake data, and alcohol intake data, electronic device use data, and sexual and relaxation activity data.

[0066] The method may include determining the timing of medication administration based on further patient data. In specific, non-limiting examples, determining the timing of medication administration may be based on one of the following: • Intake data including food, alcohol, and / or caffeine intake data, • Exercise data and related physiological data, wherein the exercise data includes the duration of exercise, the length of exercise, and / or the intensity of exercise. • Electronic device usage data including usage time and / or duration of use, • Light exposure data including the time and duration of exposure to natural light and electron light, and Actual medication data, including missed doses and timing of doses taken earlier or later than normal.

[0067] Consuming food towards the end of the day may delay or slow the rise in melatonin levels after exogenous administration. Therefore, determining the timing of medication may involve adjusting the medication offset time.

[0068] In embodiments, if the method includes receiving sleep data including a target wake-up time, the method may include setting a target wake-up time. The target wake-up time is preferably between 5:30 a.m. and 8:30 a.m. This is because it ideally coincides with an external Zeitgeber that helps synchronize circadian rhythms, particularly natural sunrise and light intensity. The method may include setting a target wake-up time based on sleep data and / or further patient data. In some embodiments, the method may include setting a target wake-up time based on one or more of the patient goal data, such as a desired wake-up time, a desired sleep duration, and a desired sleep onset time. In some embodiments, the method may include setting a target wake-up time based on sleep data and patient goal data. For example, the desired wake-up time may be 7:00 a.m., but the average actual wake-up time may be 4:00 a.m. The method may include setting a target wake-up time as an intermediate value between the desired wake-up time and the actual wake-up time, for example, 5:30 a.m. As treatment progresses and the patient's actual wake-up time moves toward the target wake-up time, the method may include updating the target wake-up time based on the actual wake-up time and the target wake-up time.

[0069] More generally, the method may include updating the target wake-up time based on sleep data. Updating the target wake-up time may be based on sleep data, patient goal data, and / or the target wake-up time. Updating the target wake-up time may be based on one or more of the actual wake-up time, actual sleep duration, and actual sleep onset time.

[0070] In one or more embodiments, the method may include indicating the target wake-up time to the patient and / or clinician.

[0071] In some embodiments, the target wake-up time may be determined externally to the system implementing the method. For example, the patient and / or clinician may determine the target wake-up time and input it into the system.

[0072] In one or more embodiments, the method may include updating the melatonin dosage as the patient progresses, establishes a consistent wake-up time, and begins to develop a more regular sleep pattern synchronized with the circadian rhythm. The method may include updating the melatonin dosage based on sleep data and / or further patient data. Updating the dosage may be based on the difference between the actual wake-up time and the target wake-up time. The method may include increasing the dosage if the difference is greater than a first threshold difference, e.g., 2 hours, over a threshold number of days, e.g., 14 or 30 days. Updating the dosage may also be based on the actual wake-up time, the target wake-up time, and the desired wake-up time. For example, the method may include decreasing the dosage if the difference between the actual wake-up time and the desired wake-up time is less than a second threshold difference over a threshold number of days, or if the difference between the actual wake-up time and the target wake-up time is less than a second threshold difference over a threshold number of days.

[0073] The method may further include providing one or more therapeutic behavioral recommendations. Providing one or more therapeutic behavioral recommendations may be for the patient and / or the clinician. Providing one or more therapeutic behavioral recommendations may be based on sleep data and / or further patient data. One or more therapeutic behavioral recommendations may include any of the following: exercise recommendations (e.g., timing, type, duration, and intensity of exercise), intake recommendations (e.g., timing of meals, expiration dates, upper limits and expiration dates for caffeine), relaxation recommendations (e.g., timing of baths, recommended relaxation techniques such as meditation), sun exposure recommendations (e.g., intensity, wavelength, and duration of sun exposure), and activity recommendations (e.g., expiration dates for electronic devices).

[0074] The timing of medication administration may be determined based on the patient's compliance with one or more therapeutic behavioral recommendations.

[0075] The term "administered" is one of the technologies and means that a therapy is provided or given to a patient. With respect to the present invention, how the therapy is administered to the patient may not be important. For example, the therapy may be administered to the patient by a healthcare provider or another third party. The therapy may be administered automatically or in response directly to user input from the patient, healthcare provider, or another third party by an electronic device such as a smartphone or other handheld device. Alternatively, the patient may administer the therapy themselves, such as by taking a pill or by meditation. The electronic device may operate on instructions provided by a second electronic device located remotely from the electronic device, such as a cloud-based server, and such instructions may be transmitted to the electronic device over a network, such as the internet or a cellular network.

[0076] If the therapy is a pharmacological therapy such as the administration of melatonin, any preferred route may be used to administer the therapy. Preferably, the route of administration is oral, rectal, nasal, topical (including buccal and sublingual), transdermal, intrathecal, transmucosal, or parenteral (including subcutaneous, intramuscular, intravenous, and intradermal) administration. Preferably, the route of administration is oral administration.

[0077] Pharmaceutical compositions containing melatonin useful for pharmacological therapy can be formulated in unit dosage forms, such as tablets and sustained-release capsules, as well as liposomes. Alternatively, the pharmaceutical compositions may be provided as unadministered gels, liquids, and syrups to be administered beforehand (by the patient, a third party, or an automated dispensing device). Useful dosage forms in connection with the present invention can be prepared by any method well known in the field of pharmacy.

[0078] As treatment progresses, the methods and uses of melatonin according to various embodiments of the invention described above may include the step of determining a melatonin dosing plan, which additionally includes indicating the dosage.

[0079] Preferably, the pharmaceutical composition and dosage form contain 0.05 to 10 mg, preferably 0.1 to 5 mg, more preferably 1 to 3 mg, for example, 2 mg of melatonin. Other preferred doses are 0.1 and 0.15 mg, then increased in stepwise increments of 0.25 mg up to 1 mg. In specific examples, the pharmaceutical composition and dosage form contain, for example, 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.4, 1.5, 1.7, 1.9, or 2.0 mg of melatonin.

[0080] As treatment progresses, the methods and uses of melatonin according to various aspects of the invention described above may take the form of iterative processing, in which an initial therapy is administered to the patient, and then additional data about the patient is processed to provide a modified therapy. This helps maintain optimal treatment of insomnia in a dynamic patient environment.

[0081] In one specific aspect, the dosage of melatonin may be increased. This may occur, for example, if the treatment does not produce the expected or desired effect on the patient, i.e., if the patient is still unable to fall asleep or maintain sleep according to the treatment plan as described above. Alternatively, in another aspect, the dosage of melatonin may be decreased. This may occur, for example, if the treatment produces the expected or desired effect on the patient, i.e., if the patient is able to fall asleep or maintain sleep according to the treatment plan and achieve the targeted wake-up time and total sleep time as described above. Once the patient achieves this regular sleep pattern, they may discontinue melatonin. For example, the daily dosage of melatonin may be decreased weekly (e.g., by the dosage increments described above) until the daily dosage reaches 0 mg, i.e., until the patient no longer needs to take melatonin to treat insomnia.

[0082] Melatonin for methods and uses according to various aspects of the invention described above may have any of the preferred features described earlier in the description of other aspects of the invention.

[0083] Figure 1 shows a computer-aided method 100 for assisting in the treatment of insomnia using melatonin according to a first embodiment. The method begins in step 100 by receiving sleep data relating to a patient. Step 104 includes determining the timing of administration for the patient to take one dose of melatonin based on the sleep data. Step 106 includes indicating the administration time. The administration time may be shown to the patient and / or clinician.

[0084] A system 110 suitable for performing any of the computer implementations disclosed herein is shown in Figure 2. The system 110 includes a patient device 115. The patient device 115 may comprise one or more processors configured to receive sleep data relating to a patient suffering from insomnia, determine the timing of medication administration for the patient to take one dose of melatonin based on the sleep data, and indicate the timing of medication administration.

[0085] In the illustrated embodiment, the patient device 115 is a smartphone and optionally includes a sensor 120. However, the invention is not limited thereto, and the patient device 115 can take many other forms, including but not limited to mobile phones, tablet computers, desktop computers, voice-activated computing systems, laptops, game systems, vehicle computing systems, wearable devices, smartwatches, smart TVs, Internet of Things devices, and drug dispensing devices.

[0086] The patient device 115 may be configured to collect data including sleep data relating to the patient and / or the immediate environment. The patient device 115 may collect sleep data and further patient data using sensor 120, which can be any combination of any other sensors capable of collecting sleep data and / or any other characteristics of the patient and / or the patient's immediate environment, such as optical sensors such as cameras, temperature sensors, acoustic sensors such as microphones, accelerometers, air pressure sensors, airborne particulate matter sensors, global positioning sensors, humidity sensors, electric field sensors, magnetic field sensors, moisture sensors, air quality sensors and Geiger counters, electroencephalograms (EEGs), heart rate monitors, pulse oxygen saturators, or polysomnography-related data and / or any other characteristics of the patient and / or the patient's immediate environment. Although sensor 120 is shown to form part of the patient device 115, in some embodiments sensor 120 may be separate from the patient device 115 and be able to communicate remotely with the patient device 115. In other embodiments sensor 120 may be omitted from the patient device 115.

[0087] Alternatively, or in addition, information about the patient and / or the patient's immediate environment can be obtained through other mechanisms, including manual data entry using the human interface device of the patient device 115.

[0088] The patient device 115 may include memory (not shown) for storing sleep data and / or further patient data. Such data may also be stored in a database 135 as a networked or cloud-based data storage device.

[0089] The patient device 115 may have one or more applications (or apps) installed on a storage medium associated with the patient device (not shown). One or more apps may be configured to perform any of the computer implementation methods disclosed herein. One or more applications may be configured to control data acquisition via the sensor 120 and / or to assist the patient in providing data about current symptoms and / or the immediate environment. One or more applications may be downloaded from a network, for example, from a website or an online application store.

[0090] In this embodiment, the system 110 further comprises a data processing device 130 that is communicably coupled to the patient device 115 via a network 125. In the illustrated embodiment, the network 125 is the Internet, but the present invention is not limited thereto, and the network 125 can be any network that enables communication between the patient device 115 and the data processing device 105, such as a cellular network or a combination of the Internet and a cellular network.

[0091] The data processing device 130 complements the patient device 115 and can perform one or more steps of any of the computerized implementation methods disclosed herein. For example, in some embodiments, the patient device may receive sleep data and provide the sleep data to the data processing device 130. The data processing device 130 may then determine the timing for the patient to take melatonin based on the sleep data. The data processing device 130 may then provide the timing to either or both the patient device 115 or the clinician device 140, which may indicate the timing of the medication. In this way, the data processing device provides networked, server-based, or cloud-based processing capabilities to a system for performing the computerized implementation method.

[0092] The data processing device may be coupled to a database 135 that can store sleep data or further patient data as described earlier in this specification.

[0093] In this embodiment, system 100 includes a clinician data processing device 140 which is communicably coupled to patient devices 115 and data processing devices 130 via a network 125. The clinician data processing device 140 may be substantially similar to the patient device 115 and provide a similar set of functions. Specifically, the clinician data processing device 140 enables the matching of data, including sleep data, relating to the patient and / or the patient's immediate environment. The clinician data processing device 140 is thought to be physically located within the clinician's facility during its use, such as a sleep clinic, a physician's surgery room, a pharmacy, or any other medical facility, e.g., a hospital. The clinician data processing device 140 may include one or more sensors, such as sensor 120, that can collect information about the patient and / or their local environment, and / or may be configured to control one or more separate sensors, such as sensor 120.

[0094] The clinician data processing device 140 is typically used by a medically trained person with appropriate data security access rights, and therefore, it may be possible to access more advanced functions than those available through the patient device 115. For example, the clinician data processing device 140 may be able to access a patient's medical history, generate melatonin prescriptions for the patient, and order medication for treatment. Access to these functions may be controlled by security policies implemented by the local processor or data processing device 105.

[0095] The data processing device 130 and / or the clinician device 140 may have installed applications that are compatible with or identical to the applications installed on the patient device 115.

[0096] It will be understood that various steps of the computer implementation methods disclosed herein can be performed in any combination by any one or more processors of the patient device 115, the data processing device 130, and the clinician device 140. For example, all steps may be performed by the clinician device 140, which receives sleep data from the patient device 115 via the network 125, and optionally by the data processing device 130. In a further embodiment, all steps may be performed on a networked backend on the data processing device 130, with the patient device 115 and the clinician device 140 serving as human interfaces for collecting and presenting data. In yet another embodiment, all steps may be performed on the patient device 115, with the clinician device 140 merely collecting relevant data from the patient device 115 to notify or instruct the clinician.

[0097] It will also be understood that one or more components of system 100 may be omitted depending on the application. For example, in a sleep clinic setting, the computer implementation method of disclosure will be performed only on the clinician device 140. Alternatively, the method may be performed only on the patient device in a home setting.

[0098] Figure 3 shows a user interface sequence 150 suitable for display on the patient device 115 when the system 110 is performing one of the computer implementations disclosed herein.

[0099] In this embodiment, the display 151 of the user interface sequence 150 includes selection buttons 152 and 154 for initiating user input. The selection buttons include a target wake-up time selection button 152 and a target sleep onset selection button 154.

[0100] The target wake-up time selection button 152 responds to user activation by initiating the target wake-up time input 153 of the user interface sequence 150. The target wake-up time input 153 allows the user to enter a target wake-up time. In this way, the user interface sequence 150 allows the system to receive sleep data in the form of a target wake-up time.

[0101] The target sleep onset selection button 154 responds to user activation by initiating the target sleep onset time input 155 of the user interface sequence 150. The target sleep onset time input 155 allows the user to enter a target sleep onset time. In this way, the user interface sequence 150 enables the system to receive sleep data in the form of a target sleep onset time.

[0102] After receiving the target wake-up time and / or target sleep-on time, the system may determine the timing for the patient to take melatonin based on the inputs received in the target wake-up time input 153 and / or target sleep-on time input 154. In this embodiment, the system indicates the timing of the medication to the patient via the medication time indicator 156 of the display 151.

[0103] It will be understood that the user interface sequence in Figure 3 is merely illustrative. As extensively outlined above, the medication time may be based on other sleep data, such as actual wake-up time and sleep hunger, which may be received as patient input and / or sensor input and / or derived therefrom. The user interface sequence 150 may be modified to accommodate all such variations.

[0104] The instructions and / or flowchart steps in the above diagrams may be performed in any order unless a specific order is explicitly stated. While we have considered one exemplary set of instructions / methods, those skilled in the art will recognize that the matters herein may be combined in various ways to produce other embodiments, and that these should be understood within the context provided by this detailed description.

[0105] In some exemplary embodiments, the set of instruction / method steps described above are implemented as functional and software instructions, which are programmed with executable instructions and embodied as a set of executable instructions that are executed on a computer or machine controlled by them. Such instructions are loaded onto a processor (such as one or more CPUs) for execution. The term processor includes microprocessors, microcontrollers, processor modules or subsystems (including one or more microprocessors or microcontrollers), or other control or computing devices. A processor may refer to a single component or a set of components.

[0106] In other embodiments, the instructions / methods described herein, and the sets of data and instructions associated therewith, are stored in one or more non-temporary machines or storage devices, each implemented as a computer-readable or computer-usable storage medium or medium. Such computer-readable or computer-usable storage media or medium are considered part of an article (or product). An article or product can refer to any single or multiple manufactured components. Non-temporary machines or computer-usable media or medium as defined herein exclude signals, but such media or medium may receive and process information from signals and / or other temporary media.

[0107] Exemplary embodiments of the materials discussed herein may be implemented in whole or in part through networks, computers, or data-based devices and / or services. These include clouds, the internet, intranets, mobile devices, desktops, processors, lookup tables, microcontrollers, consumer devices, infrastructure, or other effective devices and services. The following non-exclusive definitions are provided for use in this specification and the claims.

[0108] In one embodiment, one or more instructions or steps considered herein are automated. The terms automated or automatically (and similar variations thereof) mean the controlled operation of a device, system, and / or process using a computer and / or mechanical / electrical device without the need for human intervention, observation, effort, and / or decision.

[0109] It will be understood that any components said to be joined together can be joined or connected either directly or indirectly. In the case of indirect joining, an additional component may be located between the two components said to be joined together.

[0110] In this specification, exemplary embodiments are presented in terms of a selected set of details. However, those skilled in the art will understand that many other exemplary embodiments, including different selected sets of these details, may be put into practice. The following claims are intended to cover all conceivable exemplary embodiments.

[0111] Examples of the Invention The invention will be further demonstrated by the following exemplary case study.

[0112] Case Study 1 A 64-year-old woman working as a bookkeeper developed severe insomnia that she described as "dramatically impacting her quality of life." The woman had moderately good sleep hygiene, and her only relevant medication was a nocturnal dose of 20 mg of amitriptyline, taken for pain relief from a rheumatic disease. There is no evidence that amitriptyline affects sleep, nor is there any interaction with melatonin.

[0113] The patient was found to have elevated stress levels and therefore experienced generalized anxiety. She reported that she had always had some difficulty sleeping, but this had worsened in the past 12 months after a change in her work pattern. The main problem was difficulty falling asleep, followed by sleep interruptions, and difficulty falling back asleep, resulting in an estimated 4-5 hours of sleep per night overall.

[0114] Specifically, the patient explained that they went to bed around 10:30 p.m. (not because they were sleepy, but simply because that was the time), and that it always took them one to two hours to fall asleep, during which time they did not get out of bed. Once asleep, they would wake up two or three times for unclear reasons, probably for 15 minutes each time.

[0115] The patient typically woke at 6:30 a.m. without needing an alarm clock and felt groggy. During the day, she was not excessively sleepy, scoring 1 / 24 on the Epworth Sleepiness Scale and 4 / 7 on the Generalized Anxiety Scale, both of which are normal scores (both well-known in this field). She ruled out snoring or restless legs syndrome.

[0116] Treatment: To optimize sleep onset during the initial stages of sleep restriction, which typically take several days to become effective, she was prescribed to take 2 mg of melatonin each night, 30-60 minutes before bedtime. She was explicitly instructed to take the melatonin between 11:00 PM and 11:30 PM, a time calculated using the inventive computer implementation method based on the recommended bedtime as part of behavioral optimization. In addition to melatonin therapy, she was introduced to behavioral therapy and advised to avoid caffeinated beverages after 2:00 PM and to incorporate more exercise to raise body temperature as a motivator for sleep. She was encouraged to consider taking a warm bath an hour before bedtime and to avoid excessive light exposure for two hours before bedtime. In the bedroom, time cues were removed and regular waiting times were reinforced. Sleep restriction was then introduced, initially with a midnight bedtime, which was then progressively moved earlier.

[0117] As her recommended bedtime was gradually shifted to her long-term optimal time of 11 p.m., the timing of her melatonin administration was shifted in parallel to 10 p.m. to 10:30 p.m.

[0118] Results: With sleep restriction and melatonin, falling asleep within 15 minutes of bedtime was achieved. In addition, sleep maintenance and sleep quality improved significantly. Over several weeks, bedtime was gradually moved earlier, and melatonin was taken at the optimized prescribed times.

[0119] Case Study 2 A 54-year-old part-time lawyer was suffering from increasingly intrusive insomnia. Her sleep had been poor for many years, but it had worsened significantly since her father's death six years prior.

[0120] She reported that after a warm bath at 8 p.m., she went to bed at 10:30 p.m. and had little difficulty falling asleep, but then woke up 2 to 5 times during the night and had great difficulty falling back asleep, which was her main problem. Unusually, she did not report looking at the clock at these times. She explained that she only slept 4 to 5 hours a night, woke up feeling unrested, and had difficulty concentrating during the day.

[0121] The patient had excellent sleep hygiene habits, avoiding nighttime stimulants and screen time. She was physically healthy, participated in regular exercise, and tried hypnotism and acupuncture, but without benefit.

[0122] Her body mass index was reported to be 22.2. Some anxiety was mentioned, but this was not considered a contributing factor to her sleep problems. Hot flashes were an intermittent issue, and she had been advised to undergo hormone replacement therapy (HRT) due to a meningioma.

[0123] Treatment: The patient was prescribed to take melatonin between 9:30 PM and 10:00 PM. This time was calculated using the inventive computer implementation method based on preferred timing for optimal synchronization with cognitive behavioral therapy.

[0124] Results: With melatonin and sleep restriction, the patient's sleep became more consistent. As treatment continued and her sleep improved, she discontinued melatonin. Her overall sleep improved, and she now only experiences poor sleep once a week, stating that "life has greatly improved."

[0125] Case Study 3 A 38-year-old mechanic has a long history of difficulty falling asleep, though not throughout his life. This began towards the end of his late teens, during his school years, but before that, he could sleep without difficulty from 10 p.m. until 6:30 a.m., easily waking up to his alarm clock. However, during his late teens, his sleep became delayed until the following sleep pattern was established.

[0126] Typically, the patient went to bed around 11 p.m., not because they were sleepy, but because it was the time, and lay there awake, thinking about something, until they drifted off to sleep between 3 and 4 a.m. They needed coffee to start the day. Actigraphy confirmed that the patient slept between 3 a.m. and 9 a.m. during the week, typically extending to noon on weekends (i.e., a total of 8-9 hours of sleep, which is normal).

[0127] This man has chronic insomnia, the most characteristic symptom of delayed sleep phase syndrome, which is acquired considering his previous normal sleep patterns.

[0128] Treatment: Cognitive behavioral therapy I using time-adjusted melatonin. The patient was instructed to time 2 mg of melatonin 12 hours before his lowest point of body temperature, which is two hours before his usual wake-up time of 12 noon, and therefore 10 p.m., according to a computer-administered method, and was encouraged to advance his "clock" to enable (or guarantee) sleep by 2 a.m. Subsequently, he was advised to advance this melatonin timing by 30 minutes each week, gradually shifting it to a final sleep time of 10 p.m. to 10:30 p.m. as his sleep further improved.

[0129] Patients in Case Studies 4–6 were examined at a sleep disorder center. Each patient reported a sleep disorder as the reason for evaluation.

[0130] Case Study 4 - Sleep Maintenance Disorder: Delayed Sleep Onset with Insomnia A 40-year-old teacher had chronic sleep problems for the past two years following a stressful period at work. She described a regular bedtime of 10 p.m., more routine than sleepiness, characteristic of type A insomnia. The patient reported that her main problem was difficulty falling asleep until around midnight, followed by several awakening episodes and some difficulty falling back asleep. Bedtime became an issue, and she tended to check the clock due to "concerns about not being able to fall asleep or not sleeping well." The patient needed to wake up at a regular time of 7 a.m. (with an alarm clock) for work, resulting in an estimated sleep time of <6 hours, representing a sleep efficiency of 66%. Her insomnia severity index was abnormal at 17. The patient reported decreased concentration at work. There was no history of snoring or restless legs syndrome. No daytime naps suggestive of extreme daytime sleepiness occurred during the day. There was no use of conventional sleep aids. The diagnostic tests included actigraphy and an accompanying sleep diary, which led to the conclusion that the patient had chronic insomnia.

[0131] Treatment: Previous treatment by her primary physician, including sleep hygiene advice, was insufficient to influence the desired outcome. After consulting with a sleep physician, three strategies were recommended. 1) Partially remotely delivered cognitive behavioral therapy, beginning with education on sleep and recommendations for exercise, as well as cognitive therapy to address thoughts and feelings. 2) Individual points for establishing a consistent, regular wake-up time of 7 a.m. (for work) and going to bed at 11 p.m. after a relaxation routine. 3) Melatonin administration at a time instructed by computer to be taken at 8 p.m. (13 hours after actual wake-up time). The rationale for introducing melatonin was that the initial behavioral intervention had failed, and that melatonin could help induce sleep (due to its hypnotic effect) and potentially directly affect the earlier timing of the body clock.

[0132] After 6 weeks of treatment, patients' sleep efficiency improved to >85%, and the insomnia severity index decreased to 7, consistent with reports of solid sleep, which persisted even after melatonin was discontinued after 6 weeks.

[0133] Case Study 5 - Sleep Maintenance Disorder: Early Awakening with Insomnia The 66-year-old patient had suffered from chronic insomnia (for over 10 years), during which time she had become habitually taking zopiclone. Recently, she discontinued it in accordance with current guidelines, but despite "sleep advice," she was experiencing severe sleep disturbances.

[0134] Typically, she goes to bed around 10:30 p.m., not just because she is tired or sleepy, and may fall asleep within half an hour, by 11:00 p.m., but if she does fall asleep, she wakes up briefly between 2:00 and 3:00 a.m. She eventually wakes up at 5:00 a.m. and stays in bed until 8:00 a.m., with a sleep efficiency of <60%. There is no history of snoring or restless legs syndrome suggestive of physical disturbance, and there were no notable findings in mood assessments using valid questionnaires (GAD7 for anxiety and PHQ8 for depression).

[0135] Treatment: We examined current management of these problems through behavioral changes. 1) Partially remotely delivered cognitive behavioral therapy, beginning with education about sleep and recommendations to exercise at appropriate times of the day, as well as cognitive therapy to address thoughts and feelings. 2) Individual points for establishing a regular early wake-up time of 7:00 AM, but going to bed at 10:30 PM after a stress-relieving routine. 3) Introduction of time-adjusted melatonin administration, instructed via computer-administered methods to be taken at 10 p.m. (30 minutes before the optimal time to fall asleep and 15 hours after the time to wake up). The rationale for introducing melatonin was the failure of the initial behavioral intervention and the possibility that melatonin would be optimally synchronized with CBT.

[0136] After approximately four weeks, sleep patterns became more consistent, wake times were extended, and sleep efficiency increased to >85%. After another four weeks, melatonin was discontinued.

[0137] Case Study 6 - Sleep Maintenance Disorders: Insomnia The patient presented with a long-standing history of difficulty maintaining sleep, beginning after a period of postpartum depression. Typically, she would go to bed around 10 p.m. due to drowsiness and fall asleep within 15 minutes, but would wake regularly between 2 and 3 a.m. for unclear reasons, have difficulty falling back asleep until 5 a.m., and then fall back asleep until being woken by an alarm clock around 7 a.m. Her estimated sleep time was 6 hours, and her sleep efficiency was 66%. The patient had intermittently used antihistamines to aid sleep. She was not using other sleep aids and was not undergoing behavioral therapy. She consumed caffeine in the form of chocolate. She typically exercised in the mornings. A sleep test confirmed a sleep efficiency of 60% due to post-sleep awakenings, consistent with her complaints, but did not reveal any essential pathology that could otherwise explain her insomnia.

[0138] Treatment: 1) Partially remotely delivered cognitive behavioral therapy, beginning with education about sleep and recommendations to exercise at appropriate times of the day, as well as cognitive therapy to address thoughts and feelings. 2) Individual points for establishing a consistent, regular wake-up time of 7:00 AM and going to bed at 11:00 PM after a relaxation routine. 3) Introduction of melatonin with adjusted timing, prescribed by computer to be taken at 10 p.m. (15 hours after waking time). The rationale for introducing melatonin was the failure of the initial behavioral intervention and its potential to solidify sleep.

[0139] After 6 weeks of remote CBT and melatonin, patients' sleep efficiency increased to >90%, approaching the normal 8-hour sleep requirement. Melatonin was later discontinued, and at a follow-up of 4 months, sleep remained adequate and stable.

[0140] The case study described above demonstrates that controlling the timing of melatonin administration can provide significant sleep improvements in patients with insomnia. Specifically, determining the timing of administration based on sleep data (e.g., target wake-up time, target sleep-onset time) can lead to improved sleep quality, sleep efficiency, and maintenance.

[0141] conclusion The inventors have discovered that by timing melatonin administration to match the patient's specific problems and sleep goals, effective treatments can be developed, enabling successful treatment of insomnia.

Claims

1. 1. A computer-implemented method for assisting in the treatment of insomnia with melatonin, comprising: receiving sleep data relating to a patient; determining a dosing time for the patient to take the melatonin based on the sleep data; and indicating the administration time. method.

2. 1. A pharmaceutical composition comprising melatonin for use in the treatment of insomnia, the melatonin dosing regime comprising: receiving sleep data relating to a patient; determining a dosing time for the patient to take the melatonin based on the sleep data; indicating the time of administration. composition.

3. The sleep data includes wake-up time data, The wake-up time data includes an actual wake-up time and / or a target wake-up time. The method of claim 1 or the composition of claim 2.

4. Determining the administration time includes: If the actual wake-up time is later than the target wake-up time, determining the dosing time based on the target wake-up time if the actual wake-up time is earlier than or equal to the target wake-up time; 4. The method or composition of claim 3.

5. determining a target sleep hunger based on the sleep data; determining the dosing time based on the target sleep deprivation; Optionally, determining the target sleep hunger comprises determining the target sleep hunger based on a target sleep duration. The method or composition according to any one of claims 1 to 4.

6. The type of insomnia is early morning awakening insomnia or sleep maintenance insomnia, and determining the dosage time includes determining the dosage time as 11 to 19 hours after the actual wake-up time or the target wake-up time; or The type of insomnia is sleep phase delay insomnia, and determining the dosage time includes determining the dosage time as 8 to 12 hours after the actual wake-up time or the target wake-up time. The method or composition according to any one of claims 3 to 5.

7. The sleep data includes one or more of wake time data, sleep duration, time to fall asleep, sleep quality, number of wake episodes, duration of wake episodes, and daytime sleep data. The method or composition according to any one of claims 1 to 6.

8. determining an actual sleep hunger based on the sleep data; determining the dosing time based on the actual sleep hunger; Optionally, determining the actual sleep hunger is based on sleep onset time and total sleep duration, optionally wherein the total sleep duration includes nighttime sleep duration and daytime sleep duration. The method or composition according to any one of claims 1 to 7.

9. the sleep data includes an insomnia severity rating, the method including applying a severity offset to the medication times based on the insomnia severity rating. The method or composition according to any one of claims 1 to 8.

10. Determining the medication time includes determining the medication time based on a target sleep onset time. The method or composition according to any one of claims 1 to 9.

11. The sleep data includes the target sleep onset time; or The method or composition further includes determining the target sleep onset time based on the sleep data, preferably based on wake up time data, and indicating the target sleep onset time.

11. The method or composition of claim 10.

12. receiving further patient data including one or more of patient record data, patient personal data, patient physiological data, patient goal data, environmental data, patient medication data, and patient activity data; Optionally, said further patient data comprises patient activity data including intake data; determining the administration time includes determining the administration time based on the further patient data, and optionally, on inoculation data; A method or composition according to any one of claims 1 to 11.

13. The sleep data includes a target wake-up time, and the method preferably further comprises: A desired wake-up time among the patient goal data; A desired sleep duration from the patient goal data; and setting the target wake-up time based on one or more desired sleep onset times in the patient goal data. A method or composition according to any one of claims 1 to 12.

14. The sleep data includes a target wake-up time, the method including updating the target wake-up time based on other data of the sleep data; Optionally, updating the target wake-up time comprises: an actual wake-up time in the sleep data; the actual sleep duration of the sleep data; and updating the target wake-up time based on at least one of the sleep data. determining the medication time includes determining the medication time based on the updated target wake-up time. A method or composition according to any one of claims 1 to 13.

15. updating the melatonin dosage based on the sleep data or the further patient data; Optionally, updating the dosage comprises updating the dosage based on a difference between a target wake-up time and an actual wake-up time in the sleep data; Optionally, further comprising increasing the dosage if the difference is greater than a first difference threshold for a threshold number of days, and / or further comprising decreasing the dosage if the difference is less than a second difference threshold for a threshold number of days. A method or composition according to any one of claims 1 to 14.

16. Providing one or more therapeutic action recommendations based on the sleep data or the further patient data; The one or more therapeutic action recommendations include any of an exercise recommendation, an intake recommendation, a relaxation recommendation, a sun exposure recommendation, and an activity recommendation. A method or composition according to any one of claims 1 to 15.

17. determining the dosing time includes determining the dosing time based on patient compliance with the one or more therapeutic action recommendations. A method or composition according to any one of claims 1 to 16.

18. receiving the sleep data includes receiving the sleep data via one or more of a patient input and a sensor input.

18. The method or composition according to any one of claims 1 to 17.

19. A system for assisting in the treatment of insomnia using melatonin, comprising: A processor configured to carry out the method according to any one of claims 1 to 18. system.

20. Storing computer executable instructions for carrying out the method according to any one of claims 1 to 18; Computer program products.